Conditions for medical insurance reimbursement of Ribociclib

Ribociclib is a CDK4/6 inhibitor, mainly used in female patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It is often used in combination with aromatase inhibitors as initial endocrine therapy, especially in patients who have not received systemic therapy. Clinical practice shows that this type of combination therapy can significantly extend the progression-free survival of patients and improve the disease control rate, and has gradually become one of the standards for endocrine treatment of breast cancer.

In China, the original drug of Riboxil has been approved for marketing, and the common specifications are200mg*63 tablets. Its usage is generally 600mg once a day for three consecutive weeks, followed by a one-week break, forming a 28-day medication cycle. Unlike chemotherapy, which requires frequent hospitalization, the oral administration of reboxil greatly improves the convenience of treatment for patients.

In terms of medical insurance, Riboxiclib has been included in the national medical insurance catalog, and the reimbursement scope is mainly for patients with HR+/HER2- locally advanced or metastatic breast cancer who meet the guideline recommendations. Medicare payment conditions generally require that the drug be combined with an aromatase inhibitor as initial endocrine therapy for female patients. In other words, patients can only enjoy medical insurance reimbursement if they meet the indications and combination medication requirements. Due to its high price, the inclusion of medical insurance reimbursement greatly reduces the financial burden on patients. According to the current market conditions, the price of a box of medicine is about more than 4,000 yuan. After payment from medical insurance, the actual payment amount of the patient will be significantly reduced, allowing more patients to adhere to treatment for a long time.

It is worth emphasizing that medical insurance reimbursement is not only an economic consideration, but also an important policy measure to promote the popularization of precision medicine and new anti-tumor drugs. With the gradual expansion of medical insurance coverage, innovative targeted drugs like Riboxil have the opportunity to benefit more breast cancer patients and provide them with better treatment options.

Reference materials:https://us.kisqali.com/